Medpace Holdings (MEDP) | Financial Analysis & Statements
Medpace Holdings Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
708.4M
Gross Profit
205.3M
28.98%
Operating Income
153.3M
21.63%
Net Income
135.1M
19.07%
EPS (Diluted)
$4.67
Balance Sheet Metrics
Total Assets
2.0B
Total Liabilities
1.5B
Shareholders Equity
459.1M
Debt to Equity
3.30
Cash Flow Metrics
Operating Cash Flow
164.6M
Free Cash Flow
188.1M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Medpace Holdings Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.5B | 2.1B | 1.9B | 1.5B | 1.1B |
| Cost of Goods Sold | 1.8B | 1.5B | 1.4B | 1.0B | 814.2M |
| Gross Profit | 760.6M | 656.3M | 524.5M | 432.4M | 328.2M |
| Gross Margin % | 30.1% | 31.1% | 27.8% | 29.6% | 28.7% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 197.6M | 180.2M | 161.4M | 131.4M | 108.4M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 197.6M | 180.2M | 161.4M | 131.4M | 108.4M |
| Operating Income | 534.9M | 446.9M | 336.8M | 278.7M | 198.6M |
| Operating Margin % | 21.1% | 21.2% | 17.9% | 19.1% | 17.4% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | -5.3M | 4.1M | -655.0K | 7.1M | 3.3M |
| Pre-tax Income | 542.4M | 475.9M | 335.7M | 282.9M | 201.9M |
| Income Tax | 91.3M | 71.5M | 52.9M | 37.5M | 20.0M |
| Effective Tax Rate % | 16.8% | 15.0% | 15.8% | 13.3% | 9.9% |
| Net Income | 451.1M | 404.4M | 282.8M | 245.4M | 181.8M |
| Net Margin % | 17.8% | 19.2% | 15.0% | 16.8% | 15.9% |
| Key Metrics | |||||
| EBITDA | 570.8M | 476.6M | 365.1M | 297.2M | 217.0M |
| EPS (Basic) | - | $13.06 | $9.20 | $7.57 | $5.06 |
| EPS (Diluted) | - | $12.63 | $8.88 | $7.28 | $4.81 |
| Basic Shares Outstanding | - | 30957000 | 30722000 | 32388000 | 35862000 |
| Diluted Shares Outstanding | - | 30957000 | 30722000 | 32388000 | 35862000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Medpace Holdings Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 497.0M | 669.4M | 245.4M | 28.3M | 461.3M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 376.8M | 291.1M | 275.9M | 213.2M | 150.5M |
| Inventory | - | - | - | - | - |
| Other Current Assets | 90.5M | 63.4M | 50.0M | 52.3M | 43.2M |
| Total Current Assets | 989.6M | 1.0B | 593.8M | 334.0M | 690.9M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 171.2M | 174.3M | 184.7M | 170.9M | 157.5M |
| Goodwill | 1.4B | 1.4B | 1.4B | 1.4B | 1.4B |
| Intangible Assets | 33.4M | 34.4M | 35.8M | 38.0M | 41.4M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 41.2M | 122.6M | 99.4M | 69.2M | 42.6M |
| Total Non-Current Assets | 985.8M | 1.1B | 1.1B | 1.0B | 969.0M |
| Total Assets | 2.0B | 2.1B | 1.7B | 1.4B | 1.7B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 28.1M | 32.5M | 31.9M | 33.1M | 25.7M |
| Short-term Debt | - | - | - | 50.0M | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 52.8M | 53.6M | 40.4M | 47.5M | 27.6M |
| Total Current Liabilities | 1.3B | 1.1B | 925.1M | 803.5M | 557.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 113.6M | 126.2M | 142.1M | 138.9M | 131.0M |
| Deferred Tax Liabilities | 1.4M | 1.8M | 2.4M | 1.1M | 1.1M |
| Other Non-Current Liabilities | 57.7M | 42.7M | 28.2M | 22.7M | 17.7M |
| Total Non-Current Liabilities | 172.7M | 170.8M | 172.7M | 162.6M | 149.8M |
| Total Liabilities | 1.5B | 1.3B | 1.1B | 966.1M | 707.0M |
| Equity | |||||
| Common Stock | 284.0K | 306.0K | 308.0K | 309.0K | 360.0K |
| Retained Earnings | -460.0M | 8.2M | -221.6M | -359.8M | 235.0M |
| Treasury Stock | 12.2M | 12.2M | 12.3M | 12.5M | 5.4M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 459.1M | 825.5M | 559.0M | 386.4M | 952.9M |
| Key Metrics | |||||
| Total Debt | 113.6M | 126.2M | 142.1M | 188.9M | 131.0M |
| Working Capital | -354.1M | -75.3M | -331.3M | -469.5M | 133.7M |
Balance Sheet Composition
Medpace Holdings Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 451.1M | 404.4M | 282.8M | 245.4M | 181.8M |
| Depreciation & Amortization | 28.1M | 29.3M | 26.3M | 22.3M | 21.1M |
| Stock-Based Compensation | 34.8M | 25.5M | 20.5M | 21.4M | 14.5M |
| Working Capital Changes | 26.3M | 152.4M | 21.4M | 63.8M | 49.7M |
| Operating Cash Flow | 643.2M | 604.0M | 348.3M | 345.7M | 246.3M |
| Investing Activities | |||||
| Capital Expenditures | -31.4M | -36.5M | -36.6M | -36.9M | -28.3M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -31.1M | -28.3M | -34.6M | -38.7M | -31.4M |
| Financing Activities | |||||
| Share Repurchases | -917.4M | -169.9M | -144.0M | -847.8M | -62.1M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | 0 | 0 | -155.0M | -274.2M | 0 |
| Financing Cash Flow | -917.4M | -169.9M | -349.0M | -1.1B | -62.1M |
| Free Cash Flow | 681.9M | 572.3M | 396.7M | 351.2M | 235.1M |
| Net Change in Cash | -305.3M | 405.8M | -35.3M | -765.0M | 152.8M |
Cash Flow Trend
Medpace Holdings Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
26.90
Forward P/E
21.97
Price to Book
25.37
Price to Sales
4.38
PEG Ratio
1.75
Profitability Ratios
Profit Margin
17.19%
Operating Margin
20.03%
Return on Equity
77.25%
Return on Assets
17.47%
Financial Health
Current Ratio
0.85
Debt to Equity
20.43
Beta
1.39
Per Share Data
EPS (TTM)
$15.26
Book Value per Share
$16.18
Revenue per Share
$94.44
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MEDP | 11.7B | 26.90 | 25.37 | 77.25% | 17.19% | 20.43 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Idexx Laboratories | 44.7B | 42.92 | 27.85 | 66.20% | 24.62% | 60.83 |
| Agilent Technologies | 32.7B | 25.67 | 4.76 | 19.95% | 18.26% | 51.39 |
| Waters | 30.5B | 28.90 | 7.24 | 29.28% | 20.30% | 60.28 |
Financial data is updated regularly. All figures are in the company's reporting currency.






